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Abstract 
Background: Little in known regarding the clinical relevance of SIRT1 in multiple sclerosis (MS).   Here, we aimed 
to evaluate mRNA expression, protein level and enzyme activity of SIRT1 in peripheral blood mononuclear cells 
(PBMCs) isolated from relapsing –remitting MS patients (RRMS) and healthy controls. Materials and Methods: 
Twenty patients with RR-MS and twenty two age- and sex-matched healthy subjects were enrolled in this case-
control study. Following PBMCs isolation, mRNA expression was evaluated by real time-PCR. SIRT1 activity and 
SIRT1 protein level were measured using a fluorometric assay and an enzyme-linked immunosorbent assay (ELISA) 
respectively, in PBMC lysates. Results: There was no statistically significant difference in the  mRNA expression of 
SIRT1 (p=0.56) and its protein levels (p=0.15)  between   MS patients and healthy subjects. By contrast, SIRT1 
enzyme activity were significantly (p=0.008) lower in RRMS patients compared with that in healthy subjects. 
Conclusion: Our findings demonstrated that enzyme activity of SIRT1 is significantly lower in PBMCs of RRMS 
patients in comparison with healthy subjects. However, more investigations are essential to clarify the role of SIRT1 
in MS pathogenesis. 
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Multiple sclerosis (MS) is a chronic 
inflammatory and demylinating disease of the central 
nervous system (CNS) which results into severe 
neurological disability with deleterious  impacts on 
quality of life. The clinical heterogeneity is the 
characteristics of MS, however, most patients 
initially exhibit a relapsing-remitting course ,which is 
followed by a secondary progressive phase. There is 
substantial evidence that several pathological 
processes including inflammation, demylination , 
axonal loss and oxidative stress  play an important role 
in MS pathogenesis(1-2). It is well-known that more 
than one mechanism  may direct toward development 
of MS and also  complicated and different mechanisms 
may prevail in various clinical course of disease(3). 
Among complicated network of molecules 
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engaged in regulation of inflammation , immune 
responses and oxidative stress,SIRT1 might be 
involved in MS pathomechanism (4, 5). 
SIRT1, a well-characterized member of  
mammalian  sirtuin (silent mating type information 
regulation 2 homolog) family, is a nicotinamide 
adenine dinucleotide-dependent protein deactylase.  
SIRT1 through function on  numerous  protein 
targets,  play important roles in several cellular 
pathways including metabolism ,apoptosis, 
inflammation, regulation of neuronal death and 
survival and oxidative stress (5-7).  
There is accumulating evidence that SIRT1 
activation exert the neuroprotective effects on  
several neurodegenerative diseases such as  
Alzhiemer,Parkinson, amyotrophic lateral sclerosis 
Huntington’s disease, and MS (5, 8-9). 
Moreover, it was reported that   SIRT1 
activation alleviated disease severity  in experimental 
autoimmune encephalomyelitis (EAE) as animal 
model of MS through preserving axonal function,  
neurological dysfunction and reducing  neuronal 
loss-induced oxidative stress and inflammation (10-
12). Furthermore, SIRT1 was significantly  expressed 
by inflammatory cells in  both active and chronic MS 
plaques (13). 
However, little is known regarding the SIRT1 
expression and its enzyme activity in peripheral 
blood mononuclear cells (PBMCs) of MS patients. 
Hence,the purpose of the present study  was to 
evaluate mRNA expression, protein level and 
enzyme activity of SIRT1 in PBMCs isolated from  
relapsing–remitting  MS patients  (RRMS ) and 
healthy controls. 
Methods 
This case-control study was conducted on 20 
patients with relapse-remitting MS (RR-MS)  and 22 
age- and sex-matched healthy subjects. All patients 
were definite MS diagnosed by a neurologist based 
on the MacDonald criteria. In details,12 patients 
were in relapse phase and rest were in rem ission 
course of disease. Also, no  patients were newly 
diagnosed cases and had not received any 
immunomodulatory and immunosuppressive drugs 
(anti-inflammatory drugs)for at least 6 month prior to 
study entry. Also, no patients had received 
corticosteroid therapy within the previous 6 months or 
for more than 6 months before inclusion in the study. 
The Expanded Disability Status Scale (EDSS) was 
used to score  degree of disability at time of blood 
sampling.  The control group was randomly 
selected among age and sex matched volunteers who 
were genetically unrelated to the patients included in 
the study. 
Relapsing-remitting course of MS was ascertained 
according to McDonald criteria in all these patients. 
All patients were recruited from Sina MS 
Center, Sina Hospital, Tehran University of Medical 
Sciences, Tehran, Iran.  
The exclusion criteria for all participants 
included a history of diabetes mellitus, malignancy, 
acute or chronic infection, cardiovascular disease, 
current smoking, any autoimmune disease and 
clinically significant systemic disease, treatment with 
immunosuppressive  and immunomudulatory  drugs 
and antioxidant supplements in previous 6 months.  
This case-contol study was approved by Tehran 
University of Medical Sciences (TUMS) Ethics 
Committee, and written informed consent was 
obtained from all participants. 
PBMC isolation 
Venous blood sample was collected from all 
participants after an overnight fast and was aliquoted 
into in heparinized tubes to separate PBMCs. PBMCs 
were isolated from freshly heparinized blood using 
Ficoll-Hypaque (Lympholyte-H; Cedarlane 
Laboratories, Hornby, ON, Canada) gradients 
centrifugation. After washing with PBS at 4°C, 
isolated PBMCs were counted and viability was tested 
using the Naebaur counting chamber after staining 
with Trypan blue. To analysis mRNA 
expression,protein expression and enzyme activity 
assay of SIRT1, PBMCs were aliquoted into  separate 
sterile 2-ml eppendorf tubes.  
SIRT1 mRNA expression 
To analysis mRNA expression, total RNA was 
extracted   from PBMCs using a Total RNA Extraction 
Miniprep kit (Viogene, Taiwan) following the 
manufacturer’s instruction.  The concentration of RNA 
was quantified  with a NanoDrop ND-1000 (Thermo 
Fisher Scientific) and RNA purity was determined by 
the 260/280 nm absorbance ratio. RNA integrity was 
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assessed by agarose gel electrophoresis.  The cDNA 
was synthesized from 1 μg of  DNase-
treated RNA using Revert Aid First Strand cDNA 
Synthesis kit (Thermo Scientific, Fermentas, USA).  
mRNA levels of target gene SIRT1 (Qiagen, 
Hilden, Germany) and housekeeping gene β-actin  
(Qiagen, Hilden, Germany) measured using 
quantitative real time -PCR in a Rotor Gene real-time 
thermocycler (Qiagen, Hilden, Germany) using 
SYBR Green detection kit (Takara Bio, Ostu, Japan). 
 To determine the linear range of the real-
time PCR assay, standard curves were generated for 
SIRT1  and β-actin  prior to performing the assay on 
test samples. The product specificity was confirmed  
by both melting curve analysis and gel 
electrophoresis. Relative gene expression was 
normalized to β-actin and calculated as 2-∆CT using 
the formula: 2-(Ct target gene-Ct β-actin) .  
The measurement of SIRT1 protein 
Quantitative measurement of SIRT1 protein in 
PBMCs was determined using a commercial 
available ELISA assay (ab123457, Abcam, 
Cambridge, MA, USA) according the manufacturer’s 
instructions. Briefly, PBMCs were lysed in a cold 
extraction buffer (provided with kit), 
which was supplemented with protease inhibitor 
cocktail and PMSF. Following centrifugation at 
16000×g for 20 min at 4°C, the supernatant was 
collected and the protein concentration of the 
resulting cell lysate was determined using the 
Bradford assay. SIRT1concentration was normalized 
for the total protein concentration of samples and 
expressed as ng/ µg of total protein. The sensitivity 
of the SIRT1 ELISA was 8 ng/ml SIRT1 standards. 
The mean inter- and intra-assay coefficient of 
variance were 7.5% and 7%, respectively. 
The assessment of SIRT1 activity 
SIRT1 activity was measured in PBMCs using 
the Cyclex SIRT1/Sir2 Deacetylase Fluorometric 
Assay Kit (CycLex, Nagano, Japan). This kit is based 
on the  NAD-dependent deacetylase activity of 
SIRT1 on the  specific fluero-substrate peptide, in the 
presence of trichostatin A, a potent inhibitor of 
SIRT1-independent histone deacetylases. The 
nuclear and cytoplasmic extracts were prepared from 
isolated PBMCs using an EpiSeeker Nuclear 
Extraction Kit (Abcam) according to the 
manufacturer’s instructions. It should be noted that 
protease inhibitor-free extracts was used to determine 
SIRT1 activity based on the kit protocol.   
Fluorescence intensity was determined by reading 
fluorescence using a microplate fluorometer (Synergy 
H4 Bio Tek) with an excitation wavelength 340 nm 
and an emission wavelength of 440 nm using a 
microplate fluorometer (Synergy H4 Bio Tek) every 1 
min for 1h. Value of SIRT1 activity was expressed as 
fluorescence intensity change [arbitrary fluorescence 
unit (AFU)] per minute and was normalized to the 
protein concentration, determined by the Bradford 
method. 
Statistical Analysis 
All data was analyzed using SPSS 19 (SPSS 
Inc., Chicago, IL, USA) . The normality was assessed 
by the Shapiro–Wilk test for data. Comparisons 
between RR-MS patients and healthy subjects were 
performed by the Mann-Whitney U test . Results  were 
presented as median (interquartile range(IQR)). 
Comparative CT method (14) was used for analysis of 
the gene expression. Statistical significance was 
considered at a p-value <0.05.  
Results 
The results of mRNA level of SIRT1 in PBMCs 
from MS patients and healthy subjects were shown in 
Figure1. As depicted in this figure, the difference 
between healthy subjects and patients with RRMS was 
not statistically significant (p=0.56). Similarly, protein 
levels of SIRT1 in RRMS patients were not 
significantly (p=0.15) decreased compared with 
healthy controls (Median (IQR); RRMS patients: 
(0.04393 ng/µg of protein (0.03199 ng/µg of total 
protein -0.06073 ng/µg of protein); healthy subjects: 
(0.08843 ng/µg of protein (0.02799 ng/µg of protein - 
0.1124 ng/µg of protein) (Figure 2). 
By contrast, SIRT1 enzyme activity were 
significantly (p=0.008) lower in RRMS patients 
(Median (IQR); 293 AFU/mg of protein (207 AFU/mg 
of protein -397.2 AFU/mg of protein))  compared with 
that in  healthy subjects (541.6 AFU/mg of protein 
(379.5 AFU/mg of protein -745.5 AFU/mg of protein)) 
(Figure 3). 
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Discussion 
In present study, we found that mRNA levels 
and protein expression of SIRT1 tended to be higher 
(albeit not significantly) in PBMCs of RRMS 
patients in comparison with those in healthy controls. 
Interestingly, we demonstrated that SIRT1 activity 
were significantly lower in PBMCs of MS patients 
than in control group. As far as we know this the first 
report of decreased SIRT1 activity in PBMCs of MS 
patients compared to controls. 
Compared to our previous study in which all 
patients were in relapse phase , we included RRMS 
patients in both relapse and remission phase of 
disease in current study. 
With regard to mRNA levels and protein 
expression of SIRT1, our findings are inconsistent 
withPenissi  et al. in which observed that protein 
levels of SIRT1 in plasma from MS patients  was 
significantly increased when compared to levels of 
control subjects (15). 
 However, it was demonstrated that mRNA 
levels and protein expression of SIRT1 were 
significantly reduced in PBMCs of MS patients 
during relapse compared to those in healthy subjects 
(13).  
It is evident that SIRT1 downregulates  NF-
Kb-dependent gene expression by deacetylating 
RelA/p65 at lysine 310. More specifically, NF-Kb 
activation caused upregulation of pro-inflammatory 
cytokines as well as several chemokines (16-18). 
Accordingly,they suggested that high expression of 
SIRT1 in MS patients may be an adaptive response to 
confront impaired inflammatory response  in MS (15). 
It is generally accepted that infiltration of 
inflammatory cells including T-lymphocytes and 
monocyte-derived macrophages into CNS and 
consequently production of large  amounts of ROS and 
inflammatory mediators  have an important role in 
neuronal damage, oligodendrocyte loss and myelin 
 
Fig. 1. TAFI polymorphism Thr 325 Ile of 8 
fetuses. L:Ladder 100bp, UD: undigested product,  
1,7: unmutant, 2,3,4,5,8: homozygote, 6: 
heterozygote 
 
Fig. 2. Protein level of SIRT1 in PBMCs from 
patients with relapsing-remitting multiple sclerosis 
(RRMS) and healthy subjects. Data are expressed 
as median (IQR) 
 
Fig. 3. Enzyme activity   of SIRT1 in PBMCs from 
patients with relapsing-remitting multiple sclerosis 
(RRMS) and healthy subjects. Data are expressed 
as median (IQR) 
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phagocytosis (19, 20). Hence, targeting SIRT1 in 
PBMCs as a mixed population of immunocompetent 




Given the key role of SIRT1 in modulating  
immune responses, inflammatory signaling, 
apoptosis and oxidative stress, it is tempting to 
speculate that low  activity of SIRT1  contributes to 
MS pathomechanism as an inflammatory, 
autoimmune and oxidative stress abnormality. 
Although further studies are needed to establish this 
concept, this explanation is supported by several 
lines of evidence. Firstly, treatment with SIRT1 
activators attenuates neural loss during optic neuritis, 
an inflammatory demyelinating optic nerve lesion 
with high frequency in MS and its animal models (9) 
. Protection against myelin breakdown in the rodents 
models  accompanying with reduced disease activity 
are also other evidence for this concept (8, 10). 
Secondly, it has been shown that loss of SIRT1 
results to increased cell activation, defective 
maintenance of T cell tolerance and subsequent 
severe disease in EAE (4). Additionally, SIRT1 
overexpressionin in chronic EAE was associated with 
reduction in inflammation and neuronal loss (8, 10). 
Notably, apoptosis in immune cells  such as  jurkat 
cells,CD4+ and CD8+ was observed in MS patients 
following SIRT1 inhibition (13) . 
Significant decreased activity of SIRT1 in MS 
patients is probably due to post-translationl 
modification of SIRT1 which is mediated in response 
to intensified chronic inflammatory 
and oxidative stress milieu in MS patients (21). This 
explanation is supported by both in vivo and in vitro  
studies showing that post-translational modification 
such as SUMOylation, phosphorylation and 
carbonylation can lead to altered activity of SIRT1 
(22, 23).  
In conclusion,our results demonstrate that 
enzyme activity of SIRT1 is significantly lower in 
PBMCs of RRMS patients in comparison with 
healthy subjects. However,more investigation with a 
large sample size and further studies on other MS 
subtypes are essential to clarify the role of SIRT1 in 
MS pathogenesis. 
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